ROADS Phase 3 Clinical Trial Data Presented at ASCO26 Show GammaTile® Provides Superior Tumor Control Leading to Patients Living Longer Without Recurrence Compared to Standard of Care in Newly Diagnosed Operable Brain Metastases

ROADS Phase 3 Clinical Trial Data Presented at ASCO26 Show GammaTile® Provides Superior Tumor Control Leading to Patients Living Longer Without Recurrence Compared to Standard of Care in Newly Diagnosed Operable Brain Metastases

PR Newswire

TEMPE, Ariz., May 30, 2026

Results support GammaTile (cesium-131 collagen tile-based radiation therapy, or TBRT) as a newstandard of care for achieving optimal outcomes in this patient populationSuperior efficacy achieved without increased side effectsData presented in late-breaking abstract at the 2026 Annual Meeting of the American Society ofClinical Oncology (ASCO26)TEMPE, Ariz., May 30, 2026 /PRNewswire/ -- GT Medical Technologies, a company focused on improving the lives of patients with brain tumors, today announced compelling new clinical data presented at ASCO26 from the randomized, multicenter ROADS trial (NCT04365374). The trial showed that patients who received surgery with GammaTile® cesium-131 collagen tile-based radiation therapy (TBRT) were more likely to survive longer without recurrence compared to the current standard of care that is surgery plus stereotactic radiation therapy (SRT) for patients with newly diagnosed operable brain metastases. The data were reported in a late-breaking abstract at ASCO26.1